Skip to main content

Table 1 The gamma pass rates (3%, 3 mm) of the 0° SGAC and MGAC in 2D-PDV

From: Comparison of 3D anatomical dose verification and 2D phantom dose verification of IMRT/VMAT treatments for nasopharyngeal carcinoma

Case # 0° SGAC MGAC
   Matrixx build-in ang corr In-house ang corr
IMRT1 100.00% 75.21% 85.48%
IMRT2 100.00% 77.89% 85.44%
IMRT3 100.00% 84.10% 89.47%
IMRT4 99.85% 84.98% 89.47%
IMRT5 99.07% 59.74% 72.30%
IMRT6 97.92% 97.06% 96.92%
IMRT7 99.79% 97.26% 98.35%
IMRT8 99.38% 87.81% 90.96%
IMRT9 96.82% 96.26% 94.21%
IMRT10 99.52% 88.71% 93.08%
VMAT1 100.00% 99.00% 98.33%
VMAT2 100.00% 98.66% 99.40%
VMAT3 99.06% 88.45% 91.80%
VMAT4 100.00% 96.02% 97.39%
VMAT5 100.00% 92.32% 92.72%
VMAT6 100.00% 96.79% 98.84%
VMAT7 99.53% 98.45% 98.79%
VMAT8 100.00% 73.66% 80.00%
VMAT9 100.00% 97.61% 98.67%
VMAT10 100.00% 94.32% 96.58%
Mean pass rate ± σ 99.55% ± 0.83% 89.22% ± 10.61% 92.41% ± 7.19%